Boron-Adhesion Peptide Conjugates for Targeted Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for muscular dystrophies and colon cancer lack effective and safe methods to slow disease progression or reduce toxicity, with existing boron compounds having limitations such as high dosages and adverse effects.
Innovation Solution
A combination of boron compounds with fibronectin or cell adhesion peptide domains, presented on solid support systems like hydrogel matrices or silica nanoparticles, to synergistically activate the boron transporter NaBC1 and integrins, reducing the need for high boron doses and minimizing toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high dosages of boron compounds are used to treat muscular dystrophies or cancer, then therapeutic efficacy is improved, but toxicity and adverse effects increase
Solution Approach 1:
The patent uses cell adhesion domains (such as RGD peptides) as intermediary molecules that bridge boron compounds to cell surface receptors (integrins). This mediation allows boron to be delivered specifically to target cells through receptor-mediated endocytosis, enhancing therapeutic efficacy while reducing the need for high systemic dosages that cause toxicity. The adhesion domains act as carriers that facilitate controlled intracellular delivery of boron.
Solution Approach 2:
The patent changes the chemical parameters of boron delivery by conjugating boron compounds with cell adhesion domains. This modification alters the pharmacokinetic properties of boron, enabling it to bind specifically to integrin receptors and be internalized by cells. The parameter change from free boron to boron-adhesion domain conjugates allows for selective targeting and reduced off-target toxicity.
2Quantity of substance
If boron compounds are combined with adjuvants like fibronectin, then lower dosages can be used, but the complexity of the composition increases
Solution Approach 1:
The patent merges boron compounds with cell adhesion domains into a single conjugate molecule. This combination integrates the therapeutic agent (boron) with the targeting mechanism (adhesion domain) into one unified structure, simplifying the overall composition compared to using separate boron and adjuvant components. The merged conjugate eliminates the need for complex mixture formulations while achieving synergistic effects at lower dosages.
3Measurement precision
If solid support systems are used to present boron and cell adhesion domains, then targeting efficiency is improved, but manufacturing complexity increases
Solution Approach 1:
The patent segments the targeting system into distinct functional modules: a boron compound moiety, a cell adhesion domain moiety, and a linker connecting them. This segmentation allows each component to be optimized and synthesized separately using established chemical methods, then assembled through well-defined conjugation chemistry. The modular approach simplifies manufacturing compared to creating entirely new complex structures, while maintaining high targeting efficiency through precise spatial arrangement of functional elements.
Data Source
AI summary
Combinations of boron compounds and adjuvants and compositions thereof are suitable for use in a method to induce myotube formation and suppress cell mortality in a mammal in need thereof and for the treatment of epithelial cancers. Compositions comprise boron compounds, adjuvants and support platforms, which enhance the effect of synergistic activation of the boron cell membrane transporter (NaBC1) and adhesion receptors in cells. The combinations and compositions are for the treatment of pathophysiological condition, which affects skeletal muscle, such as dystrophy and epithelial cancer. The combinations and compositions can be included in the field of medical chemistry or pharmacology.